{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:36:08Z","timestamp":1792643768638,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100014805","name":"Roche Italia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014805","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jtha.2022.12.029","type":"journal-article","created":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T19:16:42Z","timestamp":1677525402000},"page":"403-412","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":98,"title":["Hemophilia treatment innovation: 50 years of progress and more to come"],"prefix":"10.1016","volume":"21","author":[{"given":"Pier Mannuccio","family":"Mannucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2022.12.029_bib1","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1056\/NEJM196512302732701","article-title":"Production of high-potency concentrates of antihemophilic globulin in a closed-bag system","volume":"273","author":"Pool","year":"1965","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2022.12.029_bib2","first-page":"16","article-title":"Experience with prophylaxis in Sweden","volume":"30","author":"Nilsson","year":"1993","journal-title":"Semin Hematol"},{"key":"10.1016\/j.jtha.2022.12.029_bib3","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/MBC.0000000000000783","article-title":"A\u00a0history of prophylaxis in haemophilia","volume":"30","author":"Moreno","year":"2019","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.jtha.2022.12.029_bib4","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1111\/j.1538-7836.2006.02213.x","article-title":"The tragic history of AIDS in the hemophilia population, 1982-1984","volume":"4","author":"Evatt","year":"2006","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.12.029_bib5","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0140-6736(77)91197-7","article-title":"1-deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands\u2019 diseases","volume":"1","author":"Mannucci","year":"1977","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2022.12.029_bib6","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJM198901193200307","article-title":"Use of recombinant antihemophilic factor in the treatment of two patients with classic hemophilia","volume":"320","author":"White","year":"1989","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2022.12.029_bib7","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/blood-2006-04-017988","article-title":"A\u00a0randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study","volume":"109","author":"Astermark","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.12.029_bib8","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s12325-008-0135-6","article-title":"Systematic review of efficacy of rFVIIa and aPCC treatment for hemophilia patients with inhibitors","volume":"26","author":"Knight","year":"2009","journal-title":"Adv Ther"},{"key":"10.1016\/j.jtha.2022.12.029_bib9","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(77)90871-6","article-title":"Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder","volume":"2","author":"Brackmann","year":"1977","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2022.12.029_bib10","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1182\/blood-2011-08-369132","article-title":"The principal results of the International Immune Tolerance Study: a randomized dose comparison","volume":"119","author":"Hay","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.12.029_bib11","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2022.12.029_bib12","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJM200106073442307","article-title":"The hemophilias\u2014from royal genes to gene therapy","volume":"344","author":"Mannucci","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2022.12.029_bib13","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1365-2516.2009.02188.x","article-title":"Mortality and causes of death in Italian persons with haemophilia, 1990-2007","volume":"16","author":"Tagliaferri","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2022.12.029_bib14","doi-asserted-by":"crossref","first-page":"540","DOI":"10.7326\/M19-1208","article-title":"Data and Demographics Committee of the World Federation of Hemophilia. Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries","volume":"171","author":"Iorio","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2022.12.029_bib15","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/bloodadvances.2017006684","article-title":"Long-term safety and efficacy of emicizumab in a phase 1\/2 study in patients with hemophilia A with or without inhibitors","volume":"1","author":"Shima","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2022.12.029_bib16","first-page":"49","article-title":"Barriers and perceived limitations to early treatment of hemophilia","volume":"4","author":"Saxena","year":"2013","journal-title":"J\u00a0Blood Med"},{"key":"10.1016\/j.jtha.2022.12.029_bib17","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jtha.2022.12.029_bib18","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0049-3848(13)70150-6","article-title":"Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIII","volume":"131","author":"Schulte","year":"2013","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2022.12.029_bib19","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1517\/14728214.2015.1113254","article-title":"What is the future of PEGylated therapies?","volume":"20","author":"Swierczewska","year":"2015","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.jtha.2022.12.029_bib20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1365-2516.2012.02931.x","article-title":"PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers","volume":"19","author":"Ivens","year":"2013","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2022.12.029_bib21","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1182\/blood-2011-07-367003","article-title":"Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1\/2a study in hemophilia B patients","volume":"119","author":"Shapiro","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.12.029_bib22","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1182\/blood-2011-09-382846","article-title":"Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients","volume":"119","author":"Powell","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.12.029_bib23","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood-2015-03-630897","article-title":"Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A","volume":"126","author":"Konkle","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.12.029_bib24","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1182\/blood-2012-05-429688","article-title":"Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients","volume":"120","author":"Santagostino","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.12.029_bib25","first-page":"479","article-title":"Factor VIII replacement is still the standard of care in haemophilia A","volume":"17","author":"Aledort","year":"2019","journal-title":"Blood Transfus"},{"key":"10.1016\/j.jtha.2022.12.029_bib26","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1080\/13543784.2020.1723547","article-title":"Benefits and limitations of extended plasma half-life factor VIII products in hemophilia A","volume":"29","author":"Mannucci","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jtha.2022.12.029_bib27","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/hae.13013","article-title":"The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO","volume":"22","author":"Collins","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2022.12.029_bib28","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/hae.13438","article-title":"Defining extended half-life rFVIII-A critical review of the evidence","volume":"24","author":"Mahlangu","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2022.12.029_bib29","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.blre.2019.03.002","article-title":"Factor VIII: long-established role in haemophilia A and emerging evidence beyond haemostasis","volume":"35","author":"Samuelson Bannow","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.jtha.2022.12.029_bib30","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2022.12.029_bib31","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2022.12.029_bib32","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","article-title":"Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study","volume":"6","author":"Pipe","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2022.12.029_bib33","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2020009217","article-title":"Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies","volume":"137","author":"Callaghan","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.12.029_bib34","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1182\/blood-2021-146147","article-title":"Evaluation of the safety of emicizumab prophylaxis in persons with hemophilia A: an updated summary of thrombotic events and thrombotic microangiopathies","volume":"138","author":"Howard","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.12.029_bib35","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/hae.13972","article-title":"The critical need for postmarketing surveillance in gene therapy for haemophilia","volume":"27","author":"Konkle","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2022.12.029_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100828","article-title":"Post-authorization pharmacovigilance for hemophilia in Europe and the USA: independence and transparency are keys","volume":"49","author":"Peyvandi","year":"2021","journal-title":"Blood Rev"},{"key":"10.1016\/j.jtha.2022.12.029_bib37","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1111\/jth.15705","article-title":"Next generation FVIII mimetic bispecific antibody for hemophilia A","volume":"20","author":"Voorberg","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.12.029_bib38","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.3324\/haematol.2019.242735","article-title":"Kreuth V initiative: European consensus proposals for treatment of hemophilia using standard products, extended half-life coagulation factor concentrates and non-replacement therapies","volume":"105","author":"Peyvandi","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2022.12.029_bib39","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2022.12.029_bib40","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMe2200878","article-title":"Prepare the way for hemophilia A gene therapy","volume":"386","author":"Thornburg","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2022.12.029_bib41","author":"Mahlangu"},{"key":"10.1016\/j.jtha.2022.12.029_bib42","author":"Laffan"},{"key":"10.1016\/j.jtha.2022.12.029_bib43","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2022.12.029_bib44","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2022.12.029_bib45","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1056\/NEJMoa2119913","article-title":"Phase 1-2 trial of AAVS3 gene therapy in patients with Hemophilia B","volume":"387","author":"Chowdary","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2022.12.029_bib46","first-page":"1","article-title":"Etranacogene dezaparvovec for hemophilia B gene therapy","volume":"2","author":"Thornburg","year":"2021","journal-title":"Ther Adv Rare Dis"},{"key":"10.1016\/j.jtha.2022.12.029_bib47","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41591-022-01751-0","article-title":"Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A","volume":"28","author":"Fong","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jtha.2022.12.029_bib48","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1056\/NEJMe2024545","article-title":"Treatment of hemophilia - more amazing progress","volume":"383","author":"Mannucci","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2022.12.029_bib49","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa2002699","article-title":"BIVV001 fusion protein as factor VIII replacement therapy for hemophilia A","volume":"383","author":"Konkle","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2022.12.029_bib50","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2209226","article-title":"Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A","volume":"388","author":"von Drygalski","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2022.12.029_bib51","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.3390\/ph15101183","article-title":"Updates on novel non-replacement drugs for hemophilia","volume":"15","author":"Gualtierotti","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jtha.2022.12.029_bib52","author":"Kenet"},{"key":"10.1016\/j.jtha.2022.12.029_bib53","article-title":"Progress in the development of anti-tissue factor pathway inhibitors for haemophilia management","volume":"8","author":"Mahlangu","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jtha.2022.12.029_bib54","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1182\/bloodadvances.2019001140","article-title":"Concizumab: a novel anti-TFPI therapeutic for hemophilia","volume":"5","author":"Shapiro","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2022.12.029_bib55","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1038\/s41467-022-30102-3","article-title":"Liver-directed lentiviral gene therapy corrects hemophilia A mice and achieves normal-range factor VIII activity in non-human primates","volume":"13","author":"Milani","year":"2022","journal-title":"Nat Commun"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623000259?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623000259?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:36:34Z","timestamp":1761536194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783623000259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S1538783623000259"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2022.12.029","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hemophilia treatment innovation: 50 years of progress and more to come","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2022.12.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}